Evidence map›Paper›PMID 36975060›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2023

Evaluating the consistency with guideline recommendations for diagnosis and management of idiopathic pulmonary fibrosis in non-academic settings.

Joao De Andrade, Tracy Luckhardt, Sushilkumar Sonavane, D Ralph Crowe, Tejaswini Kulkarni, Maria Del Pilar Acosta Lara, Swati Gulati, Young Il-Kim, Rekha Ramachandran, Ronan O'Beirne

Open access · greenAbstract read
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through AKT-mTOR pathway.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Joao De AndradeUniversity of Alabama at Birmingham. joao.de.andrade@vumc.org.
Tracy LuckhardtUniversity of Alabama at Birmingham. tluckhardt@uabmc.edu.
Sushilkumar SonavaneUniversity of Alabama at Birmingham. sonavane.sushilkumar@mayo.edu.
D Ralph CroweUniversity of Alabama at Birmingham. dcrowe@uabmc.edu.
Tejaswini KulkarniUniversity of Alabama at Birmingham. tkulkarni@uabmc.edu.
Maria Del Pilar Acosta LaraUniversity of Alabama at Birmingham. mdacostalara@uabmc.edu.
Swati GulatiUniversity of Alabama at Birmingham. swati.gulati1@gmail.com.
Young Il-KimUniversity of Alabama at Birmingham. youngkim@uabmc.edu.
Rekha RamachandranUniversity of Alabama at Birmingham. rramachandran@uabmc.edu.
Ronan O'BeirneUniversity of Alabama at Birmingham. ronan@uab.edu.
University of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease with elevated mortality. Delay in diagnosis lead to worse outcomes. Guidelines developed at academic medical centers are difficult to replicate in the community.

objectivesOur primary objective was to ascertain consistency with the 2011 IPF guidelines. Our secondary objective was to conduct an interdisciplinary review to ascertain whether the evidence supported the original diagnosis of IPF or not.

methodsWe asked permission from pulmonologists to review records of patients diagnosed with IPF after 2011. We collected physician demographics and training data; patient demographics, clinical and diagnostic/management data. The clinical data and available images were reviewed by the interdisciplinary review panel.

results26 practicing pulmonologists located in the Southeast of the United States consented to participate. Mean age was 48, 70% were male and all had current certification. We reviewed data from 96 patients. The mean age was 71.4 and most were male. Only 23% had the recommended screening for a connective tissue disease and 42.6% were screened for exercise-induced hypoxemia. Among patients with available images for review (n=66), only 50% had a high-resolution CT scan. 22% of patients underwent a surgical biopsy and in only 33% of the cases three lobes were sampled. No patient had documentation that a multidisciplinary discussion occurred. In 20% of the cases with available images, the evidence supported an alternative diagnosis. 56% of eligible candidates were ever started on anti-fibrotics.

conclusionsOur findings suggest that consistency with the IPF guidelines is low in non-academic settings.

Identifiers

PMID36975060
PMCPMC10099650
OpenAlexW4361190755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.